Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Geisinger Antibiotic Allergy Pilot Program: Assess and Address (GAAP) Penicillin Allergy De-labeling
NCT05464615Phase 1Terminated
- Sponsor
- Geisinger
- Start
- Mar 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amoxicillin in penicillin allergy, sponsored by Geisinger. Primary endpoint: Success Rate of the Graded Amoxicillin Challenge at 1 year. Started Mar 2024; status: terminated.
02
Drugs
amoxicillin
03
Conditions
penicillin allergy
Beyond the preview
Go deeper on NCT05464615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05464615.